REMINDER: Our focusIR Investor Webinar takes place TONIGHT with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSLN.L Regulatory News (SLN)

  • There is currently no data for SLN

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

New Key Shareholder

5 Nov 2021 07:00

RNS Number : 4310R
Silence Therapeutics PLC
05 November 2021
 

 

Silence Therapeutics Welcomes Frazier Life Sciences as New Key Shareholder

 

 

5 November 2021

 

LONDON, Silence Therapeutics plc, AIM: SLN and Nasdaq: SLN ("Silence" or "the Company"), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today announced that a leading healthcare focused investment firm, Frazier Life Sciences Public Fund, purchased approximately $20 million of existing ordinary shares in Silence and is now a 3% shareholder in the Company.

 

Albert Cha, M.D., Ph.D., Managing Partner of Frazier Life Sciences, said: "Frazier Life Sciences is excited for the prospects for Silence's RNA interference platform technology and the potential for the Company's growth, given its promising pipeline and the noteworthy success other companies have demonstrated with RNA interference programs."

 

Mark Rothera, President and Chief Executive Officer of Silence, said: "Frazier has a track record of partnering with science-driven healthcare businesses, and we are very pleased to welcome them as an important new shareholder in Silence. This comes at an exciting time for the Company as we progress two important, wholly owned clinical stage programs and rapidly expand our pre-clinical pipeline leveraging our mRNAi GOLD™ platform."

 

Craig Tooman, Chief Financial Officer of Silence, said: "A key objective of our decision to delist from AIM and focus our efforts on Nasdaq was to attract institutional healthcare funds like Frazier. This is exactly what we envisioned, and we look forward to continuing to expand our global shareholder base."

 

Founded in 1991, Frazier Healthcare Partners is a leading provider of growth and venture capital to healthcare companies. With over $7.1 billion total capital raised, Frazier has invested in more than 200 companies, with investment types ranging from company creation and venture capital to publicly traded companies and buyouts of profitable lower-middle market companies. Headquartered in Menlo Park, Calif., the Frazier Life Sciences team invests globally in private and publicly traded companies that develop and commercialize innovative biopharmaceuticals to address important unmet medical needs. Since 2005, 61 Frazier Life Sciences portfolio companies, many of which were created or seeded by Frazier, have completed IPOs or M&As. For more information about Frazier Life Sciences, visit their website at www.frazierhealthcare.com/life-sciences.

 

 

Enquiries:

 

Silence Therapeutics plc

Gem Hopkins, Head of IR and Corporate Communications

ir@silence-therapeutics.com

 

 

Tel: +1 (646) 637-3208

Investec Bank plc (Nominated Adviser and Broker)

Daniel Adams/Gary Clarence

 

  Tel: +44 (0) 20 7597 5970

European PR

Consilium Strategic Communications

Mary-Jane Elliott/ Angela Gray / Chris Welsh

silencetherapeutics@consilium-comms.com

 

Tel: +44 (0) 20 3709 5700

 

About Silence Therapeutics

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, to inhibit the expression of specific target genes thought to play a role in the pathology of diseases with significant unmet need. Silence's proprietary mRNAi GOLD™ platform can be used to create siRNAs (short interfering RNAs) that precisely target and silence disease-associated genes in the liver, which represents a substantial opportunity. Silence's wholly owned product candidates include SLN360 designed to address the high and prevalent unmet medical need in reducing cardiovascular risk in people born with high levels of lipoprotein(a) and SLN124 designed to address iron-loading anemia conditions. Silence also maintains ongoing research and development collaborations with AstraZeneca, Mallinckrodt Pharmaceuticals, and Hansoh Pharma, among others. For more information, please visit https://www.silence-therapeutics.com/.

 

 

Forward-Looking Statements

Certain statements made in this announcement are forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other securities laws, including with respect to the Company's clinical and commercial prospects and the anticipated timing of data reports from the Company's clinical trials. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates, and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,' 'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking statements, including those risks identified in the Company's most recent Admission Document and its amended Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on April 29, 2021. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring after the date of this announcement except as required by law or by any appropriate regulatory authority.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCEAFFLEDDFFAA
Date   Source Headline
23rd Jul 20205:02 pmRNSResults of EGM
22nd Jul 20204:29 pmRNSHolding(s) in Company
22nd Jul 20204:24 pmRNSHolding(s) in Company
21st Jul 20207:00 amRNSSilence Therapeutics to Participate in Conferences
16th Jul 20207:00 amRNSMallinckrodt Exercise of Options
2nd Jul 202010:50 amRNSHolding(s) in Company
2nd Jul 20207:00 amRNSCircular and notice of general meeting
30th Jun 202012:39 pmRNSHolding(s) in Company
29th Jun 20204:55 pmRNSHolding(s) in Company
23rd Jun 20207:00 amRNSBusiness Update
23rd Jun 20207:00 amRNSSubmission of Registration Statement to the US SEC
10th Jun 20205:58 pmRNSHolding(s) in Company
10th Jun 20207:00 amRNSResults of AGM
5th Jun 20204:33 pmRNSHolding(s) in Company
1st Jun 20204:19 pmRNSAdditional Listing
29th May 20204:41 pmRNSSecond Price Monitoring Extn
29th May 20204:36 pmRNSPrice Monitoring Extension
29th May 20209:37 amRNSPDMR Shareholding
21st May 20204:28 pmRNSGrant of Share Options
20th May 20207:00 amRNSNASDAQ Intention to List
20th May 20207:00 amRNSBroker Appointment
20th May 20207:00 amRNSCompany Update
14th May 20207:00 amRNSParticipation at RBC Virtual Healthcare Conference
12th May 20204:12 pmRNSHolding(s) in Company
12th May 20209:30 amRNSPDMR Dealing
7th May 20207:00 amRNSNotice of AGM
20th Apr 20203:28 pmRNSAdditional listing – correction
20th Apr 20207:00 amRNSPDMR Dealing and Additional Listing
17th Apr 20209:34 amEQSEdison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
16th Apr 20207:00 amRNSSilence Therapeutics publication of Annual Report
14th Apr 20207:00 amRNSFinal results year ended 31 December 2019
9th Apr 20207:00 amRNSSilence Announces COVID-19 Partnership
2nd Apr 20207:00 amRNSPresentation at Conference and Notice of Results
1st Apr 20204:12 pmRNSAdditional Listing
31st Mar 202011:51 amRNSHolding(s) in Company
30th Mar 20203:00 pmRNSHolding(s) in Company
25th Mar 20202:56 pmEQSEdison Investment Research Limited: Edison issues update on Silence Therapeutics (SLN)
25th Mar 20207:01 amRNSR&D Update
25th Mar 20207:00 amRNSCollaboration with AstraZeneca
17th Mar 20204:42 pmRNSSecond Price Monitoring Extn
17th Mar 20204:36 pmRNSPrice Monitoring Extension
17th Mar 202012:07 pmRNSSecond Price Monitoring Extn
17th Mar 202012:02 pmRNSPrice Monitoring Extension
13th Mar 202012:07 pmRNSSecond Price Monitoring Extn
13th Mar 202012:02 pmRNSPrice Monitoring Extension
10th Mar 20201:23 pmRNSHolding(s) in Company
2nd Mar 202012:24 pmRNSHolding(s) in Company
19th Feb 20209:14 amRNSHolding(s) in Company
18th Feb 20207:03 amRNSSilence to Present at Cowen Health Care Conference
17th Feb 202010:00 amRNSSilence Launches Scientific Advisory Board

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.